BRIDGEBIO PHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.25 USD | +1.49% |
|
+0.24% | -37.75% |
Chart calendar BridgeBio Pharma, Inc.
53cae00.Bq13Ch-Qp7bNASp7-uFAFah0nq8z-LYiZOm-JqRPCQc.Qc4ZUFzTnverRmgYmbUTbO0c8uZFk9pxAqboUO4kPkZx-hQnL8mK__9pZw~4538311ebbb2af40b2942cc871846faa
Upcoming events on BridgeBio Pharma, Inc.
Past events on BridgeBio Pharma, Inc.
| 05/04/2024 | American College of Cardiology Scientific Meeting |
| 03/04/2024 19:20 | Cantor Muscular Dystrophy Symposium |
| 05/03/2024 14:10 | TD Cowen Healthcare Conference |
| 22/02/2024 12:30 | Q4 2023 Earnings Release |
| 08/01/2024 16:15 | JPMorgan Healthcare Conference |
| 28/11/2023 15:00 | Evercore ISI HealthCONx Conference |
| 12/11/2023 16:15 | ATTRibute CM Phase 3 Study Results Call |
| 12/11/2023 15:19 | American Heart Association Scientific Meeting |
| 02/11/2023 11:30 | Q3 2023 Earnings Release |
| 12/09/2023 15:50 | Morgan Stanley Global Healthcare Conference |
| 28/08/2023 13:30 | ATTRibute CM Phase 3 Study Results Call |
| 28/08/2023 11:45 | European Society of Cardiology Congress - Marianna Fontana |
| 27/08/2023 10:15 | European Society of Cardiology Congress - Julian Gillmore |
| 26/08/2023 16:15 | European Society of Cardiology Congress - Alan Xian Ji |
| 03/08/2023 12:30 | Q2 2023 Earnings Release |
| 17/07/2023 13:00 | Phase 3 ATTRibute-CM Clinical Study Results Call |
| 21/06/2023 17:00 | Annual General Meeting |
| 17/06/2023 22:30 | Endocrine Society Conference - Update on pediatric growth disorders |
| 17/06/2023 22:00 | Endocrine Society Conference - PTH – Relevant biology, pathophysiology, and therapeutics |
| 17/06/2023 22:00 | Endocrine Society Conference - Late Breaking II |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 40,6 26,7 51.79% | 8,25 22,5 -63.37% | 69,7 78,3 -10.92% | 77,6 80,3 -3.36% | 9,30 11,3 -17.31% | 137 |
|
EBITDA Million USD | Released Forecast Spread | -266 -268 0.65% | -474 -469 -1.06% | -577 -557 -3.53% | -505 -500 -1.16% | -593 -535 -10.93% | -512 |
|
EBIT Million USD | Released Forecast Spread | -266 -272 2.05% | -474 -458 -3.7% | -577 -551 -4.6% | -512 -499 -2.64% | -607 -568 -6.87% | -553 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -289 -293 1.63% | -505 -483 -4.65% | -586 -576 -1.9% | -485 -469 -3.32% | -653 -635 -2.82% | -609 |
|
Net income Million USD | Released Forecast Spread | -261 -271 3.76% | -449 -431 -4.1% | -563 -534 -5.42% | -481 -477 -0.79% | -643 -624 -3.05% | -613 |
|
EPS USD | Released Forecast Spread | -2,48 -2,87 13.63% | -3,80 -3,62 -4.97% | -3,90 -3,74 -4.31% | -3,26 -3,21 -1.52% | -3,95 -3,87 -2.15% | -3,22 |
| Announcement Date | 02/03/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 12,9 21,6 -40.28% | 1,69 4,47 -62.13% | 73,7 25,0 195.03% | 0,34 4,67 -92.76% | 1,87 5,03 -62.8% | 1,83 3,23 -43.49% | 1,64 2,99 -45.18% | 4,09 4,49 -8.8% | 1,75 3,79 -53.96% | 92,0 | 4,26 | 4,27 | 26,8 | 18,7 |
|
EBITDA Million USD | Released Forecast Spread | -166 -148 -11.88% | -151 -169 10.89% | -71,8 -96,4 25.55% | -124 -146 15% | -129 -116 -11.03% | -125 -132 5.62% | -141 -133 -5.61% | -156 -140 -11.47% | -175 -145 -20.71% | -143 | -142 | -153 | -148 | |
|
EBIT Million USD | Released Forecast Spread | -166 -140 -18.16% | -151 -163 7.08% | -80,2 -111 27.86% | -124 -139 10.73% | -129 -116 -11.36% | -126 -119 -5.95% | -146 -122 -19.5% | -158 -127 -23.71% | -177 -144 -22.84% | -117 | -154 | -159 | -98,9 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -152 -140 -8.83% | -201 -176 -14.37% | -2,56 -80,4 96.82% | -140 -154 8.68% | -141 -125 -12.52% | -143 -132 -8.06% | -161 -134 -19.57% | -179 -142 -26.83% | -170 -165 -3.07% | -99,7 | -158 | -164 | -158 | |
|
Net income Million USD | Released Forecast Spread | -147 -118 -24.45% | -196 -163 -20.55% | -9,86 -93,7 89.48% | -137 -143 4.08% | -138 -128 -7.62% | -140 -126 -10.86% | -158 -129 -22.65% | -177 -133 -32.9% | -168 -158 -6.25% | -122 | -164 | -167 | -165 | |
|
EPS USD | Released Forecast Spread | -1,01 -0,85 -19.02% | -1,35 -1,11 -22.09% | -0,07 -0,67 89.56% | -0,93 -0,99 5.89% | -0,92 -0,85 -8.18% | -0,92 -0,83 -10.92% | -0,98 -0,83 -17.69% | -1,08 -0,81 -32.63% | -0,96 -0,92 -4.25% | -0,51 | -0,91 | -0,93 | -0,83 | -0,72 |
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for BridgeBio Pharma, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BBIO Stock
- Calendar BridgeBio Pharma, Inc.
